In the USA, the Food & Drug Authority (FDA) has given permission to Duke University Medical Center to offer cord blood therapy to children with neurological conditions including:

  • Autism spectrum disorder
  • Autism
  • Cerebral palsy
  • Hydrocephalus
  • Apraxia of speech
  • Hypoxia ischemia, cerebral
  • Drowning; anoxia

Cerebral palsy affects
1 in 400 children

1 in 100 people have a form of autism

Cells4Life has already provided customer samples to Duke as part of a series of clinical trials over the past couple of years. The FDA approval to allow expanded access to treatment means more families with a child affected by a neurological disorder will be able to travel to Duke University for therapy.

The latest clinical trial NCT03327467 requires participants to have access to cord blood unit in a private bank. This can be their own cord stem cells, or those belonging to a sibling. The unique properties of cells found in the umbilical cord mean for sibling therapy only a partial match is required.

There is a 75% chance that siblings will be a partial match

Just last week, we have released a further two samples to Duke for the treatment for two little boys with Cerebral Palsy. We wish them and their families the very best of luck for the treatment.

Pin It on Pinterest